

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
MUHRER ET AL.

Art Unit: 1614

INTERNATIONAL APPLICATION NO: PCT/EP2005/003062

FILED: 22 MARCH 2005

U.S. APPLICATION NO: 10/593,401

35 USC §371 DATE: 13 NOVEMBER 2006

FOR: PHARMACRUTICAL COMPOSITIONS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

There listed references were cited in the International Search Report and were cited in a search report (copy enclosed) in a corresponding British application. Copies of all references are enclosed.

With respect to WO 00/61275, only the abstract is in English. This English abstract provides a concise explanation of the relevance.


With respect to WO 04/108266, a copy of US Patent Application 2006/0115539 is attached as its English equivalent.

With respect to JP 61136534, a copy of an English translation of the abstract is enclosed herewith. This English abstract provides a concise explanation of the relevance.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7877



John W. Kung
Attorney for Applicants
Reg. No. 44,199

Date: 8/14/08